Granted Patent
B2
US 12,606,550 · App. 17/995,564 · Granted Apr 21, 2026
Methods for synthesis of CHK1 inhibitors
Inventors:
Michael Schwaebe (San Mateo, CA); Thorsten Rosner (San Mateo, CA); Dalian Zhao (San Mateo, CA); Ross Miller (San Mateo, CA); Rich Dulina (San Mateo, CA); Michael Humora (San Mateo, CA); Stephen E. Gottschling (San Mateo, CA)
Assignee:
CRT Pioneer Fund LP
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present technology relates to processes, compounds, compositions, and methods useful for coupling reactions. Also, the present disclosure provides for novel intermediates, compositions of matter, and processes relating to the Chk1 inhibitor, SRA737.
Claims (4)
1 . A crystalline form of a compound salt of formula IX:
having an X-ray powder diffraction (XRPD) pattern comprising peaks, in terms of 2-theta, at about 5.9°, about 11.8°, about 14.5°, about 18.7°, about 19.3°, about 20.6°, about 20.9°, about 23.0°, and about 24.7°.
2 . The crystalline form of claim 1 , wherein the crystalline form further comprises peaks, in terms of 2-theta, at about 11.3°, about 14.8°, about 17.8°, about 18.4°, about 19.0°, about 20.2°, about 21.2°, about 21.7°, about 23.7°, about 24.0°, and about 24.4°.
3 . The crystalline form of claim 1 , wherein the crystalline form has a Differential Scanning calorimetry (DSC) endothermic peak at about 206.26° C.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 7, 2024
From: SCHWAEBE, MICHAEL; ROSNER, THORSTEN; MILLER, ROSS; HUMORA, MICHAEL
To: SIERRA ONCOLOGY, INC.
Reel/Frame 067661/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 7, 2024
From: ZHAO, DALIAN; DULINA, RICH; GOTTSCHLING, STEPHEN
To: SIERRA ONCOLOGY, INC.
Reel/Frame 067661/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2024
From: SIERRA ONCOLOGY LLC
To: CRT PIONEER FUND LP
Reel/Frame 066993/0284 →
CHANGE OF NAME
Recorded Apr 3, 2024
From: SIERRA ONCOLOGY INC.
To: SIERRA ONCOLOGY LLC
Reel/Frame 067001/0610 →
Continuity (2)
Provisional Application
63006305
· Apr 7, 2020
References Cited (256)
US 3773778A
· Hoehn et al.
· 1973
[cited by applicant]
US 4107288A
· Oppenheim et al.
· 1978
[cited by applicant]
US 5145684A
· Liversidge et al.
· 1992
[cited by applicant]
US 8058045B2
· Collins et al.
· 2011
[cited by applicant]
US 8367658B2
· Collins et al.
· 2013
[cited by applicant]
US 8530468B2
· Collins et al.
· 2013
[cited by applicant]
US 8618121B2
· Collins et al.
· 2013
[cited by applicant]
US 9040540B2
· Collins et al.
· 2015
[cited by applicant]
US 9155726B2
· Humphries et al.
· 2015
[cited by applicant]
US 9345705B2
· Shumway et al.
· 2016
[cited by applicant]
US 9403797B2
· Collins et al.
· 2016
[cited by applicant]
US 9663503B2
· Collins et al.
· 2017
[cited by applicant]
US 9765059B2
· Collins et al.
· 2017
[cited by applicant]
US 20100249112A1
· O'Connor et al.
· 2010
[cited by applicant]
US 20160208339A1
· So et al.
· 2016
[cited by applicant]
US 20170158776A1
· Feltquate et al.
· 2017
[cited by applicant]
US 20200157638A1
· Hassig et al.
· 2020
[cited by applicant]
US 20200397796A1
· Hassig et al.
· 2020
[cited by applicant]
US 20220184091A1
· Hassig et al.
· 2022
[cited by applicant]
US 20220226338A1
· Hassig et al.
· 2022
[cited by applicant]
CA 2870837A1
· 2013
[cited by applicant]
CN 1594392A
· 2005
[cited by applicant]
CN 102675858A
· 2012
[cited by applicant]
CN 103476770A
· 2013
[cited by applicant]
CN 104302635A
· 2015
[cited by applicant]
CN 112469391A
· 2021
[cited by applicant]
EA 200800441A1
· 2008
[cited by applicant]
EP 3210980
· 2017
[cited by applicant]
JP 2010540610A
· 2010
[cited by applicant]
JP 2015520753A
· 2015
[cited by applicant]
KR 102341637B1
· 2021
[cited by applicant]
RU 2009110255A
· 2010
[cited by applicant]
WO WO1995019970A1
· 1995
[cited by applicant]
WO WO1997002266A1
· 1997
[cited by applicant]
WO WO0151919A2
· 2001
[cited by applicant]
WO WO2003032984A1
· 2003
[cited by applicant]
WO WO2003035065A1
· 2003
[cited by applicant]
WO WO2003037898
· 2003
[cited by applicant]
WO WO2003093297A2
· 2003
[cited by applicant]
WO WO2003101444A1
· 2003
[cited by applicant]
WO WO2005011597A2
· 2005
[cited by applicant]
WO WO2005034869A2
· 2005
[cited by applicant]
WO WO2005037285A1
· 2005
[cited by applicant]
WO WO2005037825A2
· 2005
[cited by applicant]
WO WO2005047294A1
· 2005
[cited by applicant]
WO WO2005121126A1
· 2005
[cited by applicant]
WO WO2006039718A2
· 2006
[cited by applicant]
WO WO2006116733A2
· 2006
[cited by applicant]
WO WO2007000240A1
· 2007
[cited by applicant]
WO WO2007041712A1
· 2007
[cited by applicant]
WO WO2007044779A1
· 2007
[cited by applicant]
WO WO2007089191A1
· 2007
[cited by applicant]
WO WO2008077554A1
· 2008
[cited by applicant]
WO WO2008115369A2
· 2008
[cited by applicant]
WO WO2008117050A1
· 2008
[cited by applicant]
WO WO2009004329A1
· 2009
[cited by applicant]
WO WO2009044162A1
· 2009
[cited by applicant]
WO WO2009103966A1
· 2009
[cited by applicant]
WO WO2011029027A1
· 2011
[cited by applicant]
WO WO2013068755A1
· 2013
[cited by applicant]
WO WO2013096687A1
· 2013
[cited by applicant]
WO WO2013103836A2
· 2013
[cited by applicant]
WO WO2013171470A1
· 2013
[cited by applicant]
WO WO2018102613A2
· 2018
[cited by applicant]
WO WO2018191277A1
· 2018
[cited by applicant]
WO WO2018191299A1
· 2018
[cited by applicant]
WO WO2018222970A1
· 2018
[cited by applicant]
WO WO2019012030A1
· 2019
[cited by applicant]
WO WO2019165458A1
· 2019
[cited by applicant]
WO WO2020198510A1
· 2020
[cited by applicant]
WO WO2020232154A2
· 2020
[cited by applicant]
WO WO2021207210A1
· 2021
[cited by applicant]
Atipamula et al., Cryst. Growth Des. 2012, 12, 5, 2147-2152 (Year: 2012).
[cited by examiner]
Altschul et al., “Basic Local Alignment Search Tool,” J. Mol. Biol., Oct. 1990, 215:403-410.
[cited by applicant]
Anderson et al., “Preparation of water-soluble organic compounds by salt formation” Technobiology, vol. 1999, No. 09.
[cited by applicant]
Anonymous, “Establishment of Standards and Test Methods for New Pharmaceuticals.” Pharmaceutical Trial No. 568, Jan. 1, 2001.
[cited by applicant]
Booth et al., “The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells”, Cancer Biology & Therapy, 2018, vol. 19, No. 9, 786-796.
[cited by applicant]
Brandsma, Inger et al. Directing the Use of Ddr Kinase Inhibitors in Cancer Treatment. Expert Opinion on Investigational Drugs vol. 26,12: pp. 1341-1355 (2017).
[cited by applicant]
Bryant et al. Inhibition of the checkpoint kinase Chkl induces DNA damage and cell death in human Leukemia and Lymphoma cells. Mol Cancer. 13:147 (2014).
[cited by applicant]
Carey, F A et al. Advanced Organic Chemistry, 3rd Edition. vols. A and B, Plenum Press (1992).
[cited by applicant]
Chalmers et al., “Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden,” Genome Medicine, 2017, 9(34): 1-14.
[cited by applicant]
Cheson et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, Feb. 2007, 25(5):579-586.
[cited by applicant]
ClinicalTrials.gov identifier: NCT02797964. Dye, A. A Phase ½ Trial of SRA737 in Subjects With Advanced Cancer. Retrieved from Internet on Aug. 16, 2023 URL: https://clinicaltrials.govict2/show/NCT02797964?term=SRA737dr…
[cited by applicant]
ClinicalTrials.gov identifier: NCT02797977 :pp. 1-6 (2020). Sierra Oncology LLC - a GSK company. A Phase ½ Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects. Ret…
[cited by applicant]
ClinicalTrials.gov Identifier: NCT02854436. An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad). Record created Aug. 1, 2016. pp. 1-12…
[cited by applicant]
Colowick, Sidney P et al. Methods of Enzymology. Academic Press, Inc : pp. 1-418 (1990).
[cited by applicant]
Creighton, Thomas E et al. Proteins: Structures and Molecular Properties, 2nd Edition, W.H. Freeman and Company (1993).
[cited by applicant]
Eisenhauer et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” Eur. J. Cancer., Jan. 2009, 45(2):228-47.
[cited by applicant]
Eltabbakh, Gamal H et al. Efficacy of a Modified Regimen of Gemcitabine and Cisplatin Among Women With Recurrent Epithelial Ovarian Cancer. Journal of Solid Tumors vol. 6,2: pp. 1-7 (2016).
[cited by applicant]
Examination Report for EP Application No. 20806456.8 dated Nov. 14, 2024.
[cited by applicant]
Faustino-Rocha et al., “Estimation of rat mammary tumor volume using caliper and ultrasonography measurements,” Lab Anim (Ny), Jun. 2013, 42(6):217-24.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/618,028 dated Oct. 10, 2023.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/975,686 dated Mar. 14, 2024.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/975,686 dated Oct. 17, 2022.
[cited by applicant]
FoundationOne CDx, “Next generation sequencing oncology panel, somatic or 10. germline variant detection system,” FDA Summary of Safety and Effectiveness Data (SSED), Nov. 30, 2017, 58 pages.
[cited by applicant]
Grabocka et al., “Wild-type H-and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.” Cancer Cell 25(2) (2014): 243-256.
[cited by applicant]
Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services-FDA: pp. 1-30 (2005). Retrieved from…
[cited by applicant]
Hansen, Ryan J et al. Abstract B181: The Chk1 inhibitor, SRA737, Demonstrates Chemical Synthetic Lethality With Replication Stress-inducing Agents, Including Low-dose Gemcitabine, in Preclinical Models of Cancer. Molecu…
[cited by applicant]
Hirayama, “Handbook for Organic Compound Crystal Fabrication” 2008, 28 pages.
[cited by applicant]
Hong et al., “Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma.” Clinical Cancer Research 24(14) (2018): 3263-3272.
[cited by applicant]
Intemational Search Report and Written Opinion for International Application No. PCT/US20/25018 dated Jun. 19, 2020.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US20/32722 dated Oct. 30, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/26917 dated Jul. 2, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/35566 dated Oct. 11, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/19643 dated Apr. 30, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/23722 dated Oct. 20, 2020.
[cited by applicant]
Jensen et al., “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Medical Imaging, Oct. 2008, 8:16.
[cited by applicant]
Kawaguchi et al., “Medicinal and Crystalline polymorphism.” Journal of Human Environmental Engineering, 2002, 4(2), p. 310-317.
[cited by applicant]
Konstantinopoulos et al., “Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer.” Cancer Discovery 5(11) (2015): 1137-1154.
[cited by applicant]
Lee, Jung-Min et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type Recurrent High-grade Serous Ovarian Cancer: a First-in-class Proof-of-concept Phase 2 Study. Lancet Oncology vol. 19,…
[cited by applicant]
Lehninger, Albert L. Principles of Biochemistry 8th Edition. Worth Publishers, Inc (2021).
[cited by applicant]
Li et al., “Design, synthesis and evaluation of novel non-ATP competitive CHK1 inhibitors as chemotherapy sensitizing agents”, Journal of Chinese Pharmaceutical Sciences, 2016, 25(10), 726-736.
[cited by applicant]
Lin, Aimee Bence et al. Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair. Clinical Cancer Research vol. 23,12: pp. 3232-3240 (2017).
[cited by applicant]
Mitchell et al., “Poly (ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.” Molecular Pharmacology 78 (2010): 909-917.
[cited by applicant]
Monga et al., “Intratumoral therapy of cisplatin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer,” Am. J. Clin. Oncol., Aug. 2000, 23(4):386-392.
[cited by applicant]
Needleman et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol.. Mar. 1970, 48:443-53.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/618,028 dated Jun. 11, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/618,028 dated Jun. 16, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/975,686 dated Feb. 11, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/975,686 dated Jul. 26, 2023.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/975,686 dated Oct. 29, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/975,686 dated Aug. 2, 2024.
[cited by applicant]
Office Action for JP Application No. 2022-561181 dated Feb. 19, 2025.
[cited by applicant]
Ono, “Analysis of the Current State of Salt Selection.” Journal of Pharmaceutical Sciences, 2013, 73(3),p. 176-182.
[cited by applicant]
Oshima, “Crystallization of Polymorphs and Pseudo-polymorphs and Its Control.” Pharm Stage,2007 , 6(10).
[cited by applicant]
Partial European Search Report for EP Application No. 20806456.8 dated Feb. 10, 2023.
[cited by applicant]
Pearson et al., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci.,85(8):2444-2448 (1988).
[cited by applicant]
prnewswire.com [ online], “Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019,” Apr. 1, 2019, retrieved on Nov. 16, 2022, retrieved from URL<https://www.prnewswire.com/news-releases/sierra-r…
[cited by applicant]
Richtig et al., “Calculated tumour vol. as a prognostic parameter for survival in choroidal melanomas,” Eye, 2004, 18:619-623.
[cited by applicant]
Rundle et al., “Targeting the ATR-CHK1 axis in cancer therapy.” Cancers 9 (2017): 41.
[cited by applicant]
Sambrook, Joseph et al. Molecular Cloning: A Laboratory Manual, 2nd Edition. Cold Spring Harbor Laboratory Press : pp. 1-30 (1989).
[cited by applicant]
Sandhu, Shahneen K, et al., The Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK4827) In BRCA Mutation Carriers And Patients With Sporadic Cancer: A Phase 1 Dose-escalation Trial. The Lancet Oncology 14(9):882-892 (2…
[cited by applicant]
Scher, Howard I, et al., Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology 34(12):1402-1…
[cited by applicant]
Sen et al., “Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC.” Journal of Th…
[cited by applicant]
Sen et al., “The oral CHK1 inhibitor, SRA737, synergizes with Immune Checkpoint blockade in small cell lung cancer ;SCLC)”, MD Anderson Cancer Center, Nov. 21, 2018, p. 1.
[cited by applicant]
Sen, Triparna et al. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Research vol. 77,14: pp. 387…
[cited by applicant]
Smith et al., “Comparison of biosequences,” Adv. Appl. Math., Dec. 1981, 2(4):482-489.
[cited by applicant]
Stahl, P Heinrich et al. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Verlag Helvetica Chimica Acta and Wiley-VCH (2002).
[cited by applicant]
Supplementary European Search Report for EP Application No. 20776848.2 dated Nov. 25, 2022.
[cited by applicant]
Supplementary European Search Report for EP Application No. 18784295.0 dated Dec. 9, 2020.
[cited by applicant]
Supplementary European Search Report for EP Application No. 18809063.3 dated May 10, 2021.
[cited by applicant]
Supplementary European Search Report for EP Application No. 19757456.9 dated Dec. 9, 2021.
[cited by applicant]
Supplementary European Search Report for EP Application No. 20806456.8 dated May 11, 2023.
[cited by applicant]
Takada, “API Form Screening and Selection in the Drug Discovery Phase.” Pharm Stage, 6(10), 2007 p. 20-25.
[cited by applicant]
Tomayko et al., “Determination of subcutaneous tumor size in athymic (nude) mice,” Cancer Chemotherapy and Pharmacology, 1889, 24(3): 148-154.
[cited by applicant]
Tong et al., “drexplorer: A tool to explore dose-response relationships and drug-drug interactionsm,” Bioinformatics, May 15, 2015, 31(10): 1692-4.
[cited by applicant]
Walton et al., “The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and E˜t-MYC driven B-cell lymphoma,” Oncotarget. Jan. 19, 2016, 7(3):2329-234…
[cited by applicant]
Wang et al., “Knockdown of Chk1, Weel and Mytl by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis,” Cancer Biology & Therapy, Mar. 2004, 3(3):305-313.
[cited by applicant]
Wang, Minhua et al. Screening for Microsatellite Instability in Colorectal Cancer and Lynch Syndrome—A Mini Review. North America Journal of Medicine and Science vol. 9,1: pp. 5-11 (2016).
[cited by applicant]
Yamano, “Approach to crystal polymorphism phenomena in pharmaceutical process research.” Journal of the Society of Synthetic Organic Chemistry, Jan. 1, 2007, 65(9).
[cited by applicant]
Yin et al., “Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.” American Journal of Cancer Research 7(3) (2017): 473.
[cited by applicant]
Yuan et al., “Research progress of Chk1 and its inhibitor”, Modern Oncology, 2018, 26 (17):2797-2800.
[cited by applicant]
Berge, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
[cited by applicant]
Co-pending U.S. Appl. No. 16/844,403, inventors IAN; Collins et al., filed on Apr. 9, 2020.
[cited by applicant]
EP21784225.1 Extended European Search Report dated Jun. 4, 2024.
[cited by applicant]
Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company. see especially Part 8 : Pharmaceutical preparations and their Manufacture (1990).
[cited by applicant]
Osborne, James D et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-…
[cited by applicant]
Rowe, et al., Handbook of Pharmaceutical Excipients : 5th Edition. The Pharmaceutical Press and the American Pharmaceutical Association. 884-918 (2005).
[cited by applicant]
U.S. Appl. No. 14/396,338 Notice of Allowance dated Jan. 19, 2017.
[cited by applicant]
U.S. Appl. No. 14/396,338 Office Action dated Aug. 24, 2016.
[cited by applicant]
U.S. Appl. No. 15/587,270 Notice of Allowance dated Mar. 20, 2019.
[cited by applicant]
U.S. Appl. No. 15/587,270 Notice of Allowance dated Nov. 20, 2018.
[cited by applicant]
U.S. Appl. No. 15/587,270 Office Action dated Jun. 12, 2018.
[cited by applicant]
U.S. Appl. No. 17/124,606 Notice of Allowance dated Jun. 22, 2023.
[cited by applicant]
U.S. Appl. No. 17/124,606 Office Action dated Oct. 21, 2022.
[cited by applicant]
Flynn et al., “Correlation and prediction of mass transport across membranes. I. Influence of alkyl chain length on flux-determining properties of barrier and diffusant,” J Pharm Sci., Jun. 1972, 61(6):838-52.
[cited by applicant]
International Preliminary Report in Patentability in International Application No. PCT/US2021/025977, dated Oct. 6, 2022, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2021/025977, dated Sep. 10, 2021, 10 pages.
[cited by applicant]
Balint et al., 2001, “Activation and activities of the p53 tumour suppressor protein,” Br. J. Cancer, vol. 85, pp. 1813-1823.
[cited by applicant]
Bartek et al., 2003, “Chk1 and Chk2 kinases in checkpoint control and cancer,” Cancer Cell, vol. 3, pp. 421-429.
[cited by applicant]
Boothroyd et al., “Why Do Some Molecules Form Hydrates or Solvates?” Crystal Growth and Design vol. 18 pp. 1903-1908, 2018.
[cited by applicant]
Braga et al., “Making Crystals from Crystals: a green route to crystal engineering and polymorphism” Chemical Communications (2005) pp. 3635-3645.
[cited by applicant]
Brooks et al., 2012, “A potent chk1 inhibitor is selectively toxic in melanomas with high levels of replicative stress,” Oncogene, vol. 32, pp. 788-796.
[cited by applicant]
Carson et al., 1995, “Cancer progression and p53,” Lancet, vol. 346, pp. 1009-1011.
[cited by applicant]
Cavelier et al., 2009, “Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: Potential importance for checkpoint targeting therapy,” Cancer Res., vol. 69, pp. 865…
[cited by applicant]
Cole et al., 2011 “RNAi screen of the protein kinome identifies checkpoint kinase 1 (chk1) as a therapeutic target in neuroblastoma,” Proc. Natl. Acad. Sci. U.S.A., vol. 108, pp. 3336-3341.
[cited by applicant]
Davies et al., 2011, “Single-agent inhibition of chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo,” Oncol. Res., vol. 19, pp. 349-363.
[cited by applicant]
Di Micco et al., 2006, “Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication,” Nature, vol. 444, pp. 638-642.
[cited by applicant]
Dixon et al., 2002, “Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function,” Cell Cycle 1:6 pp. 362-368.
[cited by applicant]
Durola et al., 2007, “A New Family of Biisoquinoline Chelates”, Eur. J. Org. Chem., Issue 1, pp. 125-135.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 17152400.0, Jun. 2, 2017, 7 pages.
[cited by applicant]
Ferrao et al., 2011, “Efficacy of chk inhibitors as single agents in myc-driven lymphoma cells,” Oncogene, vol. 31, pp. 1661-1672.
[cited by applicant]
Gabriel et al., 1908, “Ubergang van der Chinoxalin zur Pyrazinreihe”, Berichte der Deutschen Chemischen Gesellschafl, vol. 40, pp. 4850-4860 (with English Abstract).
[cited by applicant]
GB Search Report for GB 0719644.7 dated Apr. 25, 2008.
[cited by applicant]
GB Search Report for GB 0803018.1 dated Jun. 17, 2008.
[cited by applicant]
Greenblatt, M. S., et al. “Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.” Cancer Research 54(18) (1994): 4855-4878.
[cited by applicant]
Guzi et al., 2011, “Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening,” Mol. Cancer Ther., vol. 10, pp. 591-602.
[cited by applicant]
Hoglund et al., 2011, “Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells, ”Clin. Cancer Res., vol. 17 (22), pp. 7067-7079.
[cited by applicant]
Intellectual Property Australia, Examination Report, Australian Patent Application No. 2012335409, Jul. 13, 2016, 2 Pages.
[cited by applicant]
Intellectual Property Australia, Examination Report, Australian Patent Application No. 2013261605, Oct. 5, 2016, 2 Pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/GB2013/051233 dated Nov. 18, 2014.
[cited by applicant]
International Preliminary Report on Patentability (IPRP) for PCT/GB2008/002259.
[cited by applicant]
International Preliminary Report on Patentability (IPRP) for PCT/GB2008/003362.
[cited by applicant]
International Preliminary Report on Patentability (IPRP) for PCT/GB2009/000438.
[cited by applicant]
International Preliminary Report on Patentability for PCT-GB2012-052786 dated Jan. 29, 2014.
[cited by applicant]
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2008/002259.
[cited by applicant]
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2008/003362.
[cited by applicant]
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2009/000438.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/GB2013/051233, dated Aug. 6, 2013, 8 pages.
[cited by applicant]
International Search Report for PCT/GB2012/052786 dated Feb. 6, 2013.
[cited by applicant]
Ioannidis et al., “Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors”, Bioorg. & Med. Chem. Lett., 2009, vol. 19, pp. 6524-6528.
[cited by applicant]
Itoh et al., 2002, “Efficient synthesis of substituted 2-aminopyrazines: FeCl3-promoted condensation of hydroxyiminoketones with aminoacetonitriles”, Tetrahedron Lett., vol. 43, pp. 9287-9290.
[cited by applicant]
Jain et al., “Polymorphism in Pharmacy” Indian Drugs (1986) vol. 23 No. 6 pp. 315-329.
[cited by applicant]
Lainchbury et al., 2011, “Checkpoint kinase inhibitors: a patent review (2009-2010)”, Exp.Opin. Ther. Pat., vol. 21, No. 8, pp. 1911-1210.
[cited by applicant]
Lainchbury et al., Oct. 19, 2012, “Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors”, J. Med. Chem., vol. 55, No. 22, pp. 10229-10240.
[cited by applicant]
Li et al., 2007, “Synthesis and in-vitro biological activity of macrocyclic urea CHK1 inhibitors”, Bioorg. & Med. Chem. Lett., vol. 17, pp. 6499-6504.
[cited by applicant]
Lieberman et al., “Pharmaceutical Dosage Forms, vol. 2” Published 1990 by Marcel Dekker, INC, pp. 462-472.
[cited by applicant]
Liu et al., 2000, “Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint,” Genes Dev., vol. 14, pp. 1448-1459.
[cited by applicant]
Morisette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews vol. 56 pp. 275-300, 2004.
[cited by applicant]
Murga et al., 2011, “Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors,” Nat. Struct. Mal. Biol., vol. 18, pp. 1331-1335.
[cited by applicant]
Office Action for Japanese Patent Application No. JP 2016-201383, Aug. 15, 2017, 8 Pages, (With English Translation).
[cited by applicant]
Russian Patent Office, Official Action, Russian Patent Application No. 2014121334, Sep. 1, 2016, 6 Pages.
[cited by applicant]
Sanchez et al., 1997, “Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25,” Science, vol. 277, pp. 1497-1501.
[cited by applicant]
Sorensen et al., 2005, “Cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair,” Nat. Cell Biol., vol. 7, pp. 195-201.
[cited by applicant]
Syljuasen et al., 2015, “Targeting lung cancer through inhibition of checkpoint kinases”, Frontiers in Genetics, vol. 6, Article 70, pp. 1-11.
[cited by applicant]
Tao et al., 2006, “Chk1 inhibitors for novel cancer treatment,” Anti-Cancer Agents in Medicinal Chemistry, vol. 6, pp. 377-388.
[cited by applicant]
Tao et al., 2007, “Macrocyclic ureas as potent and selective CHK1inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics,” Bioorg. Med. Chem. Lett., vol. 1…
[cited by applicant]
Tao et al., 2007, “Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors,” J. Med. Chem., vol. 50, pp. 1514-1527.
[cited by applicant]
Tse et al., 2007, “CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cyctotoxicity of Topoisomerase | Poisons In vitro and In vivo,” Clin. Cancer Res. vol. 13(2) pp. 591-602.
[cited by applicant]
Ugarkar et al., 2000, “Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-lodotubercidin Analogues”, Journal of Medicinal Chemistry, vol. 43, pp. 2883-2893.
[cited by applicant]
Vippagunta et al., “Crystalline Solids” Advanced Drug Delivery Reviews (2001) vol. 48 pp. 3-26.
[cited by applicant]
Walton et al., 2010, “The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106”, Molecular Cancer Therapeutics, vol. 9(1), pp. 89-100.
[cited by applicant]
Walton et al., 2012, “CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs”, Clin. Cancer Res., vol. 18, pp. 5650-5661.
[cited by applicant]
Wang et al., 1996, “UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53,” J. Natl. Cancer Inst., vol. 88, pp. 956-965.
[cited by applicant]
Weinert et al., 1989, “Control of G2 delay by the rad9 gene of Saccharomyces cerevisiae,” J. Cell Sci. Suppl., vol. 12, pp. 145-148.
[cited by applicant]
West, “Solid state chemistry and its applications”, John Wiley & Sons 2: 584 pages (2022).
[cited by applicant]
White et al., 1967, “Gattermann reaction of 3,5-dimethoxyphenylacetonitrile. Synthesis of 6,8-dioxyisoquinolines”, J. Org. Chem., vol. 32, pp. 2689-2692.
[cited by applicant]
Xiao et al., 2006, “Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-48 activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for …
[cited by applicant]
Xin et al., “Solvate Prediction for Pharmaceutical Organic Molecules with Machine Learning”, Crystal Growth and Design vol. 19 pp. 1903-1911, 2019.
[cited by applicant]
Zachos et al., 2003, “Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects,” EMBO J., vol. 22, pp. 713-723.
[cited by applicant]
Zhao et al., 2002, “Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints,” Proc. Natl. Acad. Sci. USA, vol. 99, pp. 14795-14800.
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A strategic Approach to Regulatory Considerations”, Pharmaceutical Research, Springer Berlin Heidelberg, Berlin/Heidelberg, vol. 12, No. 7, Jul. 1, 1995, pp. 945-954.
[cited by applicant]
Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry; [Topics in Current Chemistry], Springer, Berlin, DE, vol. 198, Jan. 1, 1998, pp. 163-208.
[cited by applicant]
Liu et al., “Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma.” Cancer research 77(18), 5068-5076 (2017).
[cited by applicant]
Wang et al., “Characterization of KRAS rearrangements in metastatic prostate cancer.” Cancer Discovery (2011): 35-43.
[cited by applicant]
Zangarini et al., “Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.” Bioanalysis 9(13), 1001-1010, (2017).
[cited by applicant]